Suvretta Capital Management Increases Biogen Stake

Hedge fund boosts ownership in biotech company to over 168,000 shares

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Suvretta Capital Management LLC increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 10.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund now owns 168,190 shares of the biotechnology company's stock, worth approximately $23.56 million.

Why it matters

Biogen is a major player in the biotechnology industry, particularly in the areas of multiple sclerosis and Alzheimer's disease treatments. Institutional investors closely watch the company's performance and ownership changes, as they can signal market sentiment and future growth potential.

The details

Suvretta Capital Management, a hedge fund based in New York, added 16,300 shares of Biogen to its portfolio during the third quarter. This increased the fund's total stake in the biotech firm to 168,190 shares, or about 0.11% of Biogen's outstanding stock. The shares were valued at $23.56 million at the end of the reporting period.

  • Suvretta Capital Management increased its Biogen stake during the third quarter of 2026.

The players

Suvretta Capital Management LLC

A New York-based hedge fund that focuses on long-term investments in the healthcare and technology sectors.

Biogen Inc.

A multinational biotechnology company headquartered in Cambridge, Massachusetts that specializes in treatments for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

Suvretta Capital's increased stake in Biogen suggests the hedge fund sees growth potential in the biotech company's pipeline and future performance. This could signal broader investor confidence in Biogen's ability to navigate the competitive pharmaceutical landscape and deliver innovative treatments.